Related Experiment Video
Updated: Jun 22, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Genetic aspects of familial thyroid cancer
Patrick J Morrison1, A Brew Atkinson
1Regional Medical Genetics Centre, Belfast City Hospital HSC Trust, Belfast BT9 7AB, United Kingdom. patrick.morrison@belfasttrust.hscni.net
Abstract:
Familial thyroid cancer is rare, accounting for <10% of thyroid cancer cases. Activating germline point mutations in the RET proto-oncogene are associated with multiple endocrine neoplasia types 2A, 2B, and familial medullary thyroid cancer (FMTC)-around 3% of thyroid cancer cases. Familial papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) have been identified as a distinct group of familial thyroid cancers. Sporadic nonmedullary thyroid cancer (NMTC) accounts for approximately 90% of all thyroid cancers-about 6% of NMTCs are familial (FNMTC). Although multiple endocrine neoplasia types 2A and 2B and FMTC are well characterized, very little is known about the genetic predisposition to PTC and FTC. In this paper, the genetic types of FMTC and FNMTC are reviewed and the clinical features and screening are outlined.
Insights
Familial thyroid cancer, though rare, includes well-characterized hereditary medullary thyroid cancer (FMTC) and less understood familial papillary/follicular thyroid cancer (PTC/FTC). This review covers genetic types, clinical features, and screening for these conditions.
Area of Science:
- Oncology
- Genetics
- Endocrinology
Background:
- Familial thyroid cancer comprises less than 10% of all thyroid cancer cases.
- Activating germline point mutations in the RET proto-oncogene are linked to multiple endocrine neoplasia types 2A, 2B, and familial medullary thyroid cancer (FMTC).
- Familial papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) represent a distinct group with less understood genetic predispositions.
Purpose of the Study:
- To review the genetic types of familial medullary thyroid cancer (FMTC) and familial non-medullary thyroid cancer (FNMTC).
- To outline the clinical features associated with these familial thyroid cancer subtypes.
- To describe recommended screening protocols for individuals at risk.
Main Methods:
- Literature review of genetic mutations and familial thyroid cancer syndromes.
- Analysis of clinical characteristics reported in familial thyroid cancer cases.
- Synthesis of current screening guidelines for hereditary thyroid cancer.
Main Results:
- RET proto-oncogene mutations are key in FMTC and related syndromes.
- Genetic underpinnings of familial PTC and FTC remain largely uncharacterized.
- Distinct clinical presentations exist for different familial thyroid cancer types.
Conclusions:
- While FMTC is well-defined, further research is needed into the genetics of familial PTC and FTC.
- Understanding genetic predispositions is crucial for targeted screening and early detection.
- Comprehensive management strategies should address both genetic and clinical aspects of familial thyroid cancer.
Related Concept Videos
Cancer Prevention
Some...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Cancers Originate from Somatic Mutations in a Single Cell
Cancers Originate from Somatic Mutations in a Single Cell
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
